ARVO 2018

The Association for Research in Vision and Ophthalmology conference (ARVO) is the largest gathering of eye and vision researchers in the world, attracting attendees from more than 75 countries. This annual conference is a great opportunity for researchers at all stages of their careers to establish collaborations, explore the cutting-edge advances in ophthalmic science and take part in lively critique of their own and others research. 

Moorfields Eye Charity is delighted to see a wide range of research projects being presented by researchers from Moorfields and UCL Institute of Ophthalmology and to be supporting a number of these projects and researchers. 

Below are a selected number of posters and presentations from the ARVO schedule where Moorfields Eye Charity has provided some funding of the work or its presentation at this leading conference. For a more extensive list of Moorfields and UCL Institute of Ophthalmology presentations please see the helpful guide here.


  • Professor Lyndon da Cruz

‘Improvement and stabilization of vision for 18 months after Human Embryonic Stem-cell (hESC) derived, RPE-sheet’

  • Alice Davidson

‘RNA toxicity induced by TCF4 CTG expansions is ameliorated by antisense therapeutics in a patient-derived cell model of Fuchs corneal endothelial dystrophy (FECD)’

  • Anthony Khawaja

‘Genome-wide association study of intraocular pressure identifies 83 novel loci’

  • Odysseas Georgiadis

‘Human Embryonic Stem Cell-derived Retinal Pigment Epithelium transplantation in severe neovascular Age-related Macular Degeneration: 18-month survival and structural outcomes’

  • Cynthia Yu-Wai-Man

‘Development of targeted siRNA nanotherapeutics to prevent fibrosis in experimental glaucoma filtration surgery’


Poster presentations

  • Reena Chopra

‘Development of neovascular age-related macular degeneration in fellow eyes of patients undergoing intravitreal anti-VEGF therapy at a large tertiary ophthalmic hospital’

  • Sumita Phatak

‘Prevalence of thickened choroid in eyes with a CNVM –an indicator for long term treatment’

  • Thushanthi Ramakrishnan

‘Five-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital’

  • Ella Preston

‘Mortality of patients under anti-VEGF therapy at a large tertiary ophthalmic hospital’

  • Jessica Gardner

‘X-linked cone dystrophy and Blue Cone Monochromacy caused by novel and rare L/M opsin interchange haplotypes’

  • Tjebo Heeren

‘Macular photoreceptor atrophy defines the end stage of macular telangiectasia type 2’

  • Katarina Jovanovic

‘Probing the function of Arl3 in CRISPR modified cell models’

  • Daniel Florea

‘Diabetes mellitus in MacTel Can Diabetes Mellitus be a negative prognosticator in MacTel?’

  • Marta Toth

‘Intraocular pressure lowering effect of the Hydrus Microstent implantation combined with cataract surgery in moderate to advanced glaucoma’

  • Neringa Jurkute

‘In vivo vessel volume quantification in Leber's hereditary optic neuropathy (LHON) during the disease conversion and progression’

  • Francesca Bosello

‘Visual acuity recovery following multiple evanescent white dot syndrome (MEWDS) and factors that influence this: results of a very large series’

  • Vijay Tailor  

‘Visual crowding in congenital nystagmus, sensory deficit or image motion?’

  • Alexandra Kalpadakis-Smith

‘The acuity and crowding deficits in strabismic amblyopia are stronger in the fovea than the visual periphery’